Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
A phase 3 trial of Adaptive radiotherapy in Cervical cancer, run by Peking Union Medical College Hospital, now recruiting.
Overview
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer is a phase 3 interventional study registered as NCT06641635 by Peking Union Medical College Hospital, with 440 participants planned, started 2024-11-19 and due to reach its primary completion in 2026-10-31. Interventions recorded: Moderated hypofractionated online adaptive radiotherapy, Conventional radiotherapy. Conditions recorded: Cervical Cancer, Adaptive Radiotherapy.
Linked to the technology Adaptive radiotherapy because the registry names it ("adaptive radiotherapy") among its interventions and Cervical cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialResponse Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
Shares Adaptive radiotherapy (online replanning) and the tag pipeline.
- TrialAdaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Shares Adaptive radiotherapy (online replanning) and the tag pipeline.
- TrialStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Shares Cervical cancer and the tag pipeline.
- TrialA Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Shares Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialSafety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Shares Cervical cancer and the tag pipeline.
- TrialStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Shares Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Shares Cervical cancer and the tag pipeline.